Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Editas Medicine's share price for the quarter that ended in Mar. 2024 was $7.42. Editas Medicine's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 82.23 Mil. Therefore, Editas Medicine's market cap for the quarter that ended in Mar. 2024 was $610.18 Mil.
Editas Medicine's quarterly market cap
increased
from Sep. 2023 ($637.02 Mil) to Dec. 2023 ($828.30 Mil) but then
declined
from Dec. 2023 ($828.30 Mil) to Mar. 2024 ($610.18 Mil).
Editas Medicine's annual market cap
declined
from Dec. 2021 ($1,816.96 Mil) to Dec. 2022 ($610.68 Mil) but then
increased
from Dec. 2022 ($610.68 Mil) to Dec. 2023 ($828.30 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Editas Medicine's Enterprise Value for Today is $173.83 Mil.
Editas Medicine Market Cap Historical Data
The historical data trend for Editas Medicine's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Editas Medicine's Market Cap
For the Biotechnology subindustry, Editas Medicine's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Market Cap distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Market Cap falls into.
Editas Medicine Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Editas Medicine's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (NAS:EDIT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Editas Medicine Market Cap Related Terms
Thank you for viewing the detailed overview of Editas Medicine's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Editas Medicine (Editas Medicine) Business Description
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EDIT has been successfully added to your 